The annual cost of Zynlonta (loncastuximab tesirine) can vary, with a reported price of $15,000 per vial. The total annual cost depends on the dosage and treatment duration for individual patients [1].
What is Zynlonta used to treat?
Zynlonta is an antibody-drug conjugate used to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) whose disease has progressed after two or more lines of systemic therapy [1].
How is Zynlonta administered?
Zynlonta is administered intravenously by a healthcare professional [1].
What is the recommended dosage for Zynlonta?
The recommended dosage for Zynlonta is 150 mcg/kg, administered every 21 days (once every three weeks) for up to one year [1].
When did Zynlonta receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Zynlonta in February 2021 [2].
What are the potential side effects of Zynlonta?
Common side effects of Zynlonta include low blood cell counts (neutropenia, anemia, thrombocytopenia), fatigue, rash, diarrhea, nausea, and elevated liver enzymes [1]. More serious side effects can include severe neutropenia, liver problems, and infusion-related reactions [1].
What is the pricing structure for Zynlonta?
The list price for Zynlonta is $15,000 per vial [1]. This price does not reflect the actual cost to patients, which can be influenced by insurance coverage, patient assistance programs, and other factors [1].
How can patients access Zynlonta support programs?
Patients prescribed Zynlonta may be eligible for financial assistance and support through the Zynlonta Co-Pay Program, which can help cover out-of-pocket costs [1].
What is the patent status of Zynlonta?
Information regarding the specific patent status and expiration dates for Zynlonta can be found on DrugPatentWatch.com [3].
Who manufactures Zynlonta?
Zynlonta is manufactured by ADC Therapeutics [2].
How does Zynlonta work?
Zynlonta is a CD19-directed antibody-drug conjugate. It works by targeting cancer cells that express the CD19 protein, delivering a cytotoxic agent directly to these cells to kill them [1].
Sources:
[1] https://www.zyan.com/zynlonta/
[2] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zynlonta-loncastuximab-tesirine-treatment-relapsed-or-refractory-diffuse-large-b-cell
[3] https://drugpatentwatch.com/